[HTML][HTML] Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new …
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder promoted by the
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
[引用][C] Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new …
V Salizzato, C Borgo, L Cesaro, LA Pinna… - Oncotarget, 2016 - cir.nii.ac.jp
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing
rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic …
rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic …
[PDF][PDF] Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new …
V Salizzato, C Borgo, L Cesaro, LA Pinna… - pdfs.semanticscholar.org
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder promoted by the
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined …
V Salizzato, C Borgo, L Cesaro, LA Pinna… - Oncotarget, 2016 - europepmc.org
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder promoted by the
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined …
V Salizzato, C Borgo, L Cesaro, LA Pinna… - Oncotarget, 2016 - hero.epa.gov
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder promoted by the
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined …
V Salizzato, C Borgo, L Cesaro, LA Pinna… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder promoted by the
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …
[HTML][HTML] Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new …
V Salizzato, C Borgo, L Cesaro, LA Pinna… - Oncotarget, 2016 - oncotarget.com
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6
phosphorylation in chronic myeloid leukaemia cells: new combined... | Oncotarget Online ISSN …
phosphorylation in chronic myeloid leukaemia cells: new combined... | Oncotarget Online ISSN …
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined …
V Salizzato, C Borgo, L Cesaro, LA Pinna… - Oncotarget, 2016 - oncotarget.com
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6
phosphorylation in chronic myeloid leukaemia cells: new combined... | Oncotarget Online ISSN …
phosphorylation in chronic myeloid leukaemia cells: new combined... | Oncotarget Online ISSN …